Evogene Ltd EVGN.OQ, EVGN.O is expected to show a fall in quarterly revenue when it reports results on August 19 for the period ending March 31 2025
The Rehovot Israel-based company is expected to report a 25.6% decrease in revenue to $3.118 million from $4.19 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Evogene Ltd is for a loss of 45 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Evogene Ltd is $3.50, about 61.1% above its last closing price of $1.36
This summary was machine generated August 15 at 12:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)